| 词条 | Vobarilizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = scFv | source = zu | target = IL6R | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1628814-88-9 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C = 1118 | H = 1757 | N = 315 | O = 364 | S = 8 | molecular_weight = 256.9 kDa | UNII = 9OD8ISS64U | KEGG = D11005 | synonyms = ALX0061 }}Vobarilizumab (ALX0061) (INN) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2] This drug was developed by Ablynx NV. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association. {{monoclonals for immune system}}{{monoclonal-antibody-stub}}2. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。